Protocols
34 protocol(s) meet the specified criteria
Disease Site: Other
Protocol No.TitleStatus
11-1474AAccountability for Cancer Care through Undoing Racism and Equity (ACCURE)Open
13-2058Internet Tobacco Vendors Youth Purchase SurveyOpen
17-1493Expanded Access of Neratinib for Use with Capecitabine in Patients with Metastatic Breast Cancer and CNS MetastasisOpen (affiliates only)
A011502-CIRB-REXRex_Alliance A011502: A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin As Adjuvant Therapy For Node Positive HER2 Negative Breast Cancer: The ABC TrialOpen (affiliates only)
A031102-CIRBA Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (Tip) With High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed By High-Dose Carboplatin And Etoposide (Ti-Ce) As First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors Open
AALL0331Standard Risk B-precursor Acute Lymphoblastic LeukemiaOpen
AGCT1531A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell TumorsOpen
AMGEN359A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase 3 Study of Denosumab as Adjuvant Treatment for Women with Early-Stage Breast Cancer at High Risk of Recurrence (D-CARE)Open (affiliates only)
AMGEN482A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid in the Treatment of Bone Disease in Subjects With Newly Diagnosed Multiple MyelomaOpen (affiliates only)
APEC1621SCNCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)Open
ASG-22CE-13-2A Phase 1 Study of the Safety and Pharmacokinetics of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects with Metastatic Urothelial Cancer and Other Malignant Solid Tumors that Express Nectin-4Open
BMT-CTN-1506A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Trial of the FLT3 Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients with FLT3/ITD AMLOpen
CP-MGD014-01A Phase 1 Study to Evaluate the Safety, Immunologic and Virologic Responses of MGD014 Therapy in HIV-Infected Individuals on Suppressive Antiretroviral TherapyOpen
DELETETEST4A four part, Phase I Dose-Escalation Study of the Combinations of Concurrent BKM120 and Capecitabine,or Concurrent BKM120 and Capecitabine and Trastuzumab, in Patients with Metastatic Colon Cancer (Test4)Open
ETCTN9767-CIRBAn Open Label, Multicenter, Single arm Phase II study to evaluate the Activity and Tolerability of the novel mTOR Inhibitor, MLN0128 (TAK-228), in patients with Locally Advanced or Metastatic Transitional Cell Carcinoma of the urothelial tract whose tumors harbor a TSC1 and/or a TSC2 mutation.Open
H3B-6545-A001-101A Phase I-II multicenter, open label trial of H3B-6545, a covalent antagonist of estrogen receptor alpha, in women with locally advanced or metastatic estrogen receptor-positive, HER2 negative breast cancerOpen
INCB-18424-365A Phase III Randomized Open-Label Multi-Center Study of Ruxolitinib vs. Best Available Therapy in Patients with Corticosteroid-Refractory Chronic Graft vs Host Disease After Allogenic Stem Cell Transplantation (REACH 3)Open
LCCC1241Complementary and Alternative medicine use at UNC clinicsOpen
LCCC1527Evaluation of the Chemotherapy Toxicity Risk Score for Treatment Decision in Elderly Patients with Advanced Solid CancerOpen
LCCC1715Detection and Analysis of MERTK in Cancer PatientsOpen
LCCC1722CHART Intervention to Encourage Smoking Cessation During Treatment for Head/Neck Cancer: A Feasibility StudyOpen
LCCC1725A Phase I Study of Durvalumab (MEDI 4736) and Tremelimumab together with Radiotherapy for the adjuvant treatment of Intermediate Risk Head and Neck Squamous Cell Carcinoma Open
LCCC1726Randomized Placebo Controlled Trial of High Dose Intravenous Thiamine for the Prevention of Delirium in Allogeneic Hematopoietic Stem Cell TransplantationOpen
LCCC1734Adaptation of the Parenting Concerns Questionnaire for Patients with IllnessOpen
LCCC1735Functional Sparing of Salivary Glands Using MRI Sialography for Patients Undergoing Definitive Radiation Therapy for Head and Neck Cancers of the OropharynxOpen
LCCC1802Randomized Trial of Parotid Sparing Whole Brain RadiationOpen
LCCC1805Pediatric Oncology Tissue Procurement to Support Research on Molecular Drivers and Precision Medicine ApproachesOpen
LCCC1830-ATL-COMCompassionate use administration of autologous CAR T cells targeting the CD19 antigen and containing the inducible caspase 9 safety switchOpen
MM-398-01-01-02A Phase 1 Study in Patients Treated with MM-398 (Nanoliposomal Irinotecan, nal-IRI,) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to TreatmentOpen
NCI-10139-CIRBA Randomized Phase 2 Study of Atezolizumab in Combination with Cobimetinib versus Atezolizumab Monotherapy in Participants with Unresectable CholangiocarcinomaOpen
ONC012A Phase II Study of ONC201 in Recurrent or Metastatic Type II Endometrial CancerOpen
PCRC-14-07Caregiver-­‐guided pain management training in palliative careOpen
RTOG1008A Randomized Phase II/III Study of Adjuvant Concurrent Radiation and Chemotherapy versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors Open
SGN22E-002A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancerOpen